At the news
? BULLISHIMPACT 6/10 8-K filed Nov 2, 2026 at 16:11 ET
Neurocrine Biosciences reported Q3 2026 total revenue of $1.123B, up 41% YoY, with net product sales exceeding $1B for the first time. INGREZZA net sales guidance was raised to $2.9B-$2.925B from $2.825B-$2.875B. Non-GAAP EPS of $3.29 beat the $2.75 consensus, and revenue of $1.123B beat the $1.04B consensus.
- Q3 2026 total revenue $1.123B, up 41% YoY from $795M
- INGREZZA net product sales $801M, up 17% YoY
- CRENESSITY net product sales $211M, up 115% YoY
- VYKAT XR net product sales $107M (first contribution from Soleno acquisition)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access